We first knocked down (KD) levels of XPO1 protein expression with CRISPR ribonucleoprotein in the same MOLM-13 cell line model of FLT3-ITD AML as used in screening with three different guides (Figure 2a) and confirmed reduced protein expression via immunoblot analysis (Figure 2b). This evidence concerns the gene FLT3 and acute myeloid leukemia.